Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Install PDR’s official, FREE drug information and comparison app today! Apple | Android | Learn More
Omega-3 Fatty Acid Supplementation
The OMEGA LIFE-3 RESOLV formula leverages key metabolic pathways to stimulate the creation of resolvins, metabolic byproducts which help maintain healthy inflammation levels in the body. OmegaLife-3 Resolv combines concentrated fish oil with proprietary ingredients for a powerful combination of 1000 mg EPA and 500 mg DHA for optimal health and wellness.
Clinical research suggests fish oil can help support proper brain and eye health. In 2002 the FDA approved supplementation of DHA in infant formula. DHA is potentially important in fetal and infant neural development, in that DHA and arachidonic acid have been shown to be incorporated into brain and retinal cell membranes—particularly during the third trimester of pregnancy and early infant life.
DHA is the predominant structural fatty acid in the central nervous system and in the retina of the eyes.
EPA supports the synthesis of important compounds in the body. EPA is the precursor of thromboxane and leukotriene, compounds involved in supporting healthy circulation. They also promote healthy blood vessels.
Evidence is accumulating that increasing intakes of EPA and DHA can decrease the risk thrombosis, decrease triglyceride levels, and decrease inflammation.
The U.S. Food and Drug Administration (FDA) has stated, "Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease."1
Take four softgels daily with water.
OmegaLife-3™ and OmegaLife-3 Resolve are well tolerated. As with any dietary supplement, some gastrointestinal discomfort may be experienced.
Available in softgels.
Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol. 2008;102(8):1040-1045
Lee JH, Harris WS, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83(3):324-332.
SanGiovanni JP, Chew EY, Sperduto RD, et al. The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol. 2008;126(9):1274-1279.
SanGiovanni JP, Parra-Cabrera S, Colditz GA, Berkey CS, Dwyer JT. Meta-analysis of dietary essential fatty acids and long-chain polyunsaturated fatty acids as they relate to visual resolution acuity in healthy preterm infants. Pediatrics 2000;105:1292-8.
Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23(2):151-152.
NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size.
The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a quick-reference identification aid. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected over dosage, the drug's identity should be verified by chemical analysis.